Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dyne Therapeutics, Inc.

9.42
-0.4900-4.94%
Pre-market: 9.06-0.3600-3.82%08:01 EDT
Volume:1.70M
Turnover:15.97M
Market Cap:1.07B
PE:-2.79
High:9.71
Open:9.50
Low:9.07
Close:9.91
Loading ...

Dyne Therapeutics Inc : RBC Cuts Target Price to $36 From $41

THOMSON REUTERS
·
Yesterday

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Dyne Therapeutics Is Maintained at Neutral by JP Morgan

Dow Jones
·
22 Mar

Sector Update: Health Care Stocks Steady Premarket Friday

MT Newswires Live
·
21 Mar

U.S. RESEARCH ROUNDUP-Darden Restaurants, Nike, Optinose

Reuters
·
21 Mar

Dyne Therapeutics Inc : JP Morgan Cuts Target Price to $17 From $18

THOMSON REUTERS
·
21 Mar

Dyne Therapeutics Names Erick Lucera as CFO

MT Newswires Live
·
21 Mar

Dyne Therapeutics Names Editas Medicine's Lucera as CFO

Dow Jones
·
21 Mar

BRIEF-Dyne Therapeutics Announces Appointment of Erick J. Lucera As Chief Financial Officer

Reuters
·
21 Mar

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) to Newly Appointed Chief Financial Officer

THOMSON REUTERS
·
21 Mar

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

GlobeNewswire
·
21 Mar

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

THOMSON REUTERS
·
21 Mar

Press Release: Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

Dow Jones
·
21 Mar

Dyne Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
17 Mar

Sector Update: Health Care Stocks Decline Premarket Monday

MT Newswires Live
·
17 Mar

Dyne Therapeutics (DYN) Gets a Buy from Scotiabank

TIPRANKS
·
17 Mar

Dyne announces new long-term data from Phase 1/2 DELIVER trial of DYNE-251

TIPRANKS
·
17 Mar

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

GlobeNewswire
·
11 Mar

Dyne Therapeutics Initiated at Sector Outperform by Scotiabank

Dow Jones
·
08 Mar

Stock Track | Dyne Therapeutics Plummets 5.22% as Q4 Losses Exceed Expectations

Stock Track
·
03 Mar